ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Adia Med, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.13−0.01 (-7.14%)

Close on Oct 19, 2026

Market cap: $20.98M
P/E (TTM): –
Dividend yield: –

Adia Med, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Revenue	0.70	0.01
Cost of Revenue	0.51	0.00
Gross Profit	0.19	0.00
Research & Development	0.03	0
General & Administrative	0.48	0.14
Advertising Expenses	0.08	0.04
Operating Expenses	0.56	0.18
Operating Income	-0.37	-0.17
Interest Expense	0.03	0.01
Interest & Investment Income	0.00	0
Other Non-Operating Income	-0.03	-0.01
Pretax Income	-0.40	-0.18
Income Tax Expense	0	0
Net Income	-0.40	-0.18
EPS (Basic)(per share)	0.00	0.00
EPS (Diluted)(per share)	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	94	92
Shares Outstanding (Diluted, Weighted)(shares)	94	92
EBITDA	-0.36	-0.17

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 27.4%
Operating margin: -52.3%
Net margin: -56.5%
Return on equity, FY2025: 340.7%

Financial strength

Current ratio: 0.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 12.1%

Valuation

P/E ratio: –
Price to sales: 29.95
Price to book: –
Dividend yield: –